Longevity
Maintenance
Review
Women’s Health Clinic FAQ
How do clinicians adjust maintenance maintenance timing (e.g., 6 months vs. 12 months) based on individual HA metabolic turnover?
Maintenance and review questions after G-Shot treatment should be based on clinical findings, not a resolved timetable or assumed filler breakdown.
Direct answer
This page should avoid resolved maintenance frequency and explain that review should consider symptoms, tissue response, filler persistence, adverse effects and realistic goals. For patients, this means maintenance should be symptom-led and review-led. Earlier repeat treatment is not automatically better, and loss of feel should be assessed before adding more filler. A clinician should assess the symptoms, tissue context and goals before deciding whether any procedure is appropriate, especially when previous treatment, discomfort or expectation mismatch may change the safest plan.
This page keeps a technical treatment question patient-facing, cautious and focused on assessment rather than procedure design.
Educational only. Use this as general education before discussing suitability, timing or symptoms with a clinician. Results vary. Not a cure.
G-Shot review
At a glance
These points frame the question before assuming a combined or repeat treatment is suitable.
Key clinical context
A quick, patient-safe summary before treatment suitability is discussed.
Longevity varies
Tissue movement, metabolism, inflammation and product behaviour can all affect persistence.
Activity is not the only factor
Sexual activity alone cannot predict degradation.
Repeat treatment needs caution
Adding more filler can increase lump, pressure or overcorrection concerns.
Loss needs review
Early loss of feel may reflect swelling resolution, expectations or another issue.
Important safety note
Seek medical advice promptly for severe or worsening pelvic or vulval pain, heavy or persistent bleeding, fever, offensive discharge, urinary retention, spreading swelling, tissue colour change, allergic symptoms, fainting or feeling very unwell.
Review
Timing
Symptoms
Consent
Detailed answer
Detailed answer
The clinically useful answer explains why this question matters without turning the page into a treatment timetable or protocol.
Clinical bottom line
The decision should be based on symptoms, tissue context, realistic goals and clinician review rather than a public procedural formula.
Safety
Consent
Review
Define the purpose
Intimate HA filler behaviour is influenced by product properties, tissue environment, movement, inflammation, hydration, individual metabolism and follow-up findings.
Respect evidence limits
Sexual activity or inactivity should not be used as a stand-alone explanation for how quickly filler appears to change.
Protect expectations
A patient reporting early loss of palpable volume needs review of symptoms, expectations, swelling resolution, product behaviour and whether another diagnosis is relevant.
Keep it clinician-led
Maintenance planning should remain individual and conservative rather than implying that earlier or more frequent treatment is better.
What this means in practice
The right plan depends on symptoms, tissue health, previous procedures, healing, consent quality and whether a non-procedural route is more appropriate.
Public information can support good questions, but it should not publish injection, machine-parameter, dissolving, sequencing or re-treatment instructions.
Patient safety
Why this matters
These questions can sound technical, but the real issue is safe decision-making and realistic consent.
It protects consent
Combined or repeat treatments need clear reasons, risks and alternatives.
It protects tissue
Filler, energy, hormone and pelvic-floor factors can interact through healing, pressure, swelling and symptoms.
It protects expectations
Sexual response, satisfaction and filler longevity cannot be promised from treatment stacking.
It protects safety
Pain, urinary symptoms, infection signs and tissue change need clear review thresholds.
The safer interpretation
A conservative plan may involve staging, review, deferral or treating another contributing factor first.
This protects patients from over-treatment, unrealistic sexual claims and avoidable complication risk.
Considerations
What a consultation should consider
Consider the treatment goal, tissue quality, menopause or oestrogen context, pain, urinary symptoms, previous procedures, healing, expectations and whether another route should come first.
What changes the decision
Pain, infection symptoms, urinary problems, GSM, previous procedures, healing concerns, distress, surgery plans or unclear goals can all shift the safest next step.
Review
Timing
Symptoms
The main goal
The consultation reviews the original aim, current symptoms, pain, swelling, urinary symptoms, sexual discomfort, tissue health and what the patient means by loss of volume.
Suitability
The clinician considers whether reassurance, observation, imaging, pelvic-floor review, GSM treatment or specialist review is more appropriate than repeat filler.
Consent
Consent should explain uncertain longevity, possible non-response and the risk of overcorrection before any further treatment is considered.
Follow-up
Follow-up should document comfort, tissue response, patient-reported change and whether expectations remain realistic.
Practical expectations
A staged or delayed plan can sometimes be safer than adding another intervention quickly.
Exact procedural details, machine parameters, medicines, dissolving decisions and timing changes should be confirmed with the treating clinician.
Common concerns and myths
Common misconceptions
These myths can make combined or repeat intimate treatment sound more predictable than it is.
Myth: maintenance is always due at a resolved interval
Reality: timing should be based on review, symptoms and tissue findings.
Myth: sexual activity alone controls breakdown
Reality: filler behaviour is multifactorial and varies between patients.
Myth: early loss always means treatment failed
Reality: swelling resolution, expectation mismatch or another cause may explain the change.
Symptoms and goals
A symptom pattern can guide assessment, but it does not prove that filler, energy treatment or repeat treatment is the answer.
Public information limits
Public education should support safer decisions without teaching intimate procedures, machine parameters or re-treatment routes.
Safety checklist
Safety checklist
Use these checks before assuming another procedure is the next step.
Is the goal clear?
Clarify whether the aim is sensation, comfort, tissue quality, pelvic-floor support, maintenance, imaging review or repeat treatment.
Has sequencing been reviewed?
Combination or repeat treatment should be staged around healing, symptoms and clinical findings.
Are red flags absent?
Pause and seek clinical review for new bleeding, fever, offensive discharge, severe or worsening pain, urinary symptoms, spreading swelling, tissue colour change, allergic symptoms, persistent lumps, pressure or uncertainty about infection.
Is uncertainty documented?
Consent should explain limited evidence, variable response and possible swelling, bruising, discomfort, urinary symptoms or non-response.
Reassuring signs
Symptoms are more reassuring when mild, stable, improving and not associated with fever, colour change, retention, severe pain or systemic illness.
Review
Timing
Reasons to pause
Pause and seek clinical review for new bleeding, fever, offensive discharge, severe or worsening pain, urinary symptoms, spreading swelling, tissue colour change, allergic symptoms, persistent lumps, pressure or uncertainty about infection.
Urinary
Infection
When to escalate
When to seek medical help
Some symptoms after intimate filler or related treatment need urgent assessment rather than routine follow-up.
Use NHS 111 online
Severe or spreading symptoms
Severe pain, spreading swelling, mottling, blanching, tissue colour change or heavy bleeding should be assessed urgently.
Infection symptoms
Fever, offensive discharge, worsening burning, ulcers, pelvic pain or feeling very unwell may need prompt medical review.
Urinary or allergic symptoms
Inability to pass urine, weak stream, breathing difficulty, facial or throat swelling, widespread rash or collapse needs urgent help.
Emergency symptoms
Call 999 in a life-threatening emergency, including collapse, chest pain, breathing difficulty or sudden neurological symptoms.
Use NHS 111 for urgent advice or call 999 in a life-threatening emergency. This page is educational and does not replace individual medical assessment.
More clinical detail
Why early loss should be reviewed
Early loss of feel may not mean the product has disappeared. Swelling resolution, altered awareness, anxiety, tissue movement or another clinical issue may need to be considered.Why maintenance is not automatic
Repeat treatment should have a clear reason and a fresh risk discussion, especially if there are lumps, pressure, pain, urinary symptoms or unclear benefit.Regulatory resources
Authoritative resources
These resources support filler safety, consent and review-led maintenance decisions.
JCCP dermal filler complications guidance
UK aesthetic-practice context for safer filler governance and complications awareness.
GMC decision making and consent
UK professional guidance for consent, uncertainty and material risk.
HA filler safety systematic review
Peer-reviewed review context for adverse events and variable filler outcomes.
Next step
Book an intimate health consultation
A consultation can clarify whether symptoms fit tissue health, pelvic-floor concerns, GSM, filler-related questions, combination treatment planning, maintenance review or another cause.
▶ View Research Sources (12 Sources)
These 12 source names are selected from 98 curated sources. Additional reviewed material included peer-reviewed clinical papers; duplicate and low-relevance records were removed before display.
Educational only. This information is for education only and is not a substitute for professional medical advice, diagnosis or treatment. Results vary. Not a cure.
